We receive and publish.
THE
n last January 29, an agreement was signed at Assolombarda, at a global level, relating to the transfer of the respiratory sector by Takeda SpA to the group to which Simesa SpA belongs. The agreement is aimed at allowing the transferor to consolidate and increase its presence on the market for other product lines and to enhance the business relating to the respiratory area, especially in those countries, such as the United States, where they already held the licenses for the marketing of some particular molecules for the treatment of respiratory pathologies severe, such as asthma and COPD.
Under the agreement, Takeda transfers to the group to which Simesa belongs its branch of business dedicated to the respiratory sector and consisting of:
– in all rights to commercial, marketing, medical-scientific information, medical and market access activities relating to Alvesco, Daxas, Daliresp and Respicur products and any products under development, and the related professional figures dedicated to therapeutic area of breathing.
– in funds relating to transferred employees.
– as well as in the warehouse stock relating to the transferred products.
The transfer will be operational from 01/03/2016, or any later date, agreed between the parties, in any case no later than 01/04/2016.
There are 26 employees transferred: 23 scientific reps and 3 Area Managers. At the time of the transfer, the employment relationships of the transferred Employees will continue without interruption with Simesa SpA which will continue to apply the regulatory and economic treatments envisaged by the National Collective Labor Agreement for Chemical and Pharmaceutical Companies. As far as the supplementary contract is concerned, Simesa will apply, as required by law, its own supplementary and 2nd level contracts and practices and procedures to replace those of the Transferor.
There are no specific measures in favor of the personnel concerned.
The agreed full text: Transfer of the Takeda-Simesa branch
_________________________________________________________
Related news: AstraZeneca CEO Raises Bar for Deals After Acquisitions Spree
AstraZeneca to Buy Respiratory Drug Business From Japan's Takeda
AstraZeneca to Acquire Takeda's Respiratory Division for $ 575,000,000
AstraZeneca launches earnings alert for rosuvastatin (Crestor) generication
AstraZeneca: acquired share of 55% in Acerta Pharma for 4 billion dollars
AstraZeneca and Sanofi sign an agreement for the exchange of 210,000 chemical compoundsthe
Takeda wins rights to new anti-cancer antibody conjugate
